Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Gurupup who wrote (2520)	6/9/1998 10:08:00 AM
From: RBM	Respond to of 5736

Skippard, Did I see OTC-BB? I think that is enough to get them sued isn't it? Rob

To: Gurupup who wrote (2520)	6/9/1998 10:08:00 AM
From: gamesmistress	Respond to of 5736

More on Asensio reports...they are having a conference call today if anyone wants to listen to this. Makes me ill myself. I am not long at the moment but my mom has a few shares. Dreyfus Fund Manager Named in Chromatics Color Sciences Inc. Report Citing Wrongdoing PR Newswire - June 09, 1998 08:48 - Asensio & Co. research report cites a series of questionable transactions that harmed investors - A new research report by Asensio & Company to be published today recommends a "strong sell" of Chromatics Color Sciences, Inc., (OTC Bulletin Board: CCSI), upon findings that a series of questionable transactions led to losses for small investors and at two Dreyfus mutual funds managed by Michael Schonberg. Highlights include: -- CCSI's technology claims are false; -- CCSI's sales estimates and product claims are false; -- CCSI sold 12.4 million shares at a discount to market to private investors who then sold them to the public to reap massive gains; -- Dreyfus fund manager, Michael L. Schonberg, bought 1.875 million shares at market prices for the two Dreyfus funds he managed; -- Investors Associates Inc., the agent for CCSI's IPO, had its licenses revoked simultaneously by 20 states attorneys general, including New York's Dennis Vacco. Asensio & Company will conduct a conference call to discuss its report in detail today at 10.30 am (EST). Press are invited to call: 888-680-5190 The complete text of the Asensio & Co. report (of 8 pages) will be published on the firm's website at noon today (EST): asensio.com For information contact: Ben Trounson (extension 24) or Tory Hayes (extension 23) at: Emmanuel Kerr Kilsby: 203-406-8800 (PR NEWSWIRE) DJ: Asensio & Co.: Dreyfus Fails to Supervise Fund Manager's DJ: Asensio & Co.: Dreyfus Fails to Supervise Fund Manager's Chromatics Stock Purchases NEW YORK, June 9 /PRNewswire/ -- The following statement was issued today by Asensio & Company, Inc.: On April 13, 1998 the Dreyfus Corporation announced the appointment of a new "primary portfolio manager" for the Dreyfus Aggressive Growth Fund and the Dreyfus Premier Aggressive Growth Fund ("the Funds"). It also announced that the former manager, Michael L. Schonberg, would continue to serve as a portfolio manager of both Funds. Mr. Schonberg was appointed senior equity portfolio manager at the Dreyfus Corporation in New York on August 14, 1995. Since then he purchased at least 1.8 million shares of Chromatics Color Sciences Inc. (OTC Bulletin Board: CCSI) ("CCSI") for the Funds. Today, Asensio & Company, Inc. released an institutional research report and strong sell recommendation on Chromatics. The report clearly establishes that Chromatics' stock has little or no economic value. In fact, we believe that even the most novice analyst can readily recognize that the company has no intrinsic value or potential to ever generate earnings. Yet over the last two years Mr. Schonberg bought, held, added and still maintains a completely disproportionate amount of Chromatics in the Funds. Mr. Schonberg is a Chartered Financial Analyst with undergraduate and graduate degrees from the Massachusetts Institute of Technology and over twenty-two years of experience as a securities analyst. It is difficult to believe that Mr. Schonberg had no knowledge of Chromatics' lack of investment value or its fraudulent activities. Despite this clear evidence of wrongful utilization of mutual investors' money, Dreyfus has attempted to make Mr. Schonberg's replacement appear as a proper management action to address the Fund's poor performance. To this date Dreyfus has failed to provide forthright disclosures or restitution plans for investors who lost money in this scheme.

To: Gurupup who wrote (2520)	6/9/1998 10:09:00 AM
From: DD™	Respond to of 5736

Very Quiet Thread considering the hackjob by Arsenio Hall Co and the damage to the stock price as a result. Any comments out there? DD

To: Gurupup who wrote (2520)	6/9/1998 10:30:00 AM
From: JanyBlueEyes	Respond to of 5736

Market Trim Tabs - June 9, 1998 - Charles Biderman, President Renewed Buy: Chromatic Color Sciences (CCSI 8 3/4) Stock Craters On Rumors Of New Short Sale Recommendation & Fund Selling. Mt. Sinai Pediatric Chief Says Every Hospital & Pediatrician Will Have A CCSI Device We are again recommending the purchase of Chromatic Sciences (CCSI - 8 3/4). Since we last wrote up CCSI on May 4, the stock price has dropped almost in half - from 16 1/2 to 8 3/4. Our May 4 issue reported that Dr. Ian Holzman, Professor of Pediatrics and Chief of Newborn Medicine at NYC's Mt. Sinai Medical Center presented the successful results of a 2,441 newborn trial at this year's annual pediatric convention. At that time we quoted from Dr. Holzman's conclusion: "The Chromatics Colormate TLC-BiliTest provides an accurate and linear estimate of serum bilirubin on a wide variety of infants, including those of many skin types, gestational ages, races and phototherapy. Its use in both nurseries and neonatal intensive care units should decrease blood drawing and increase the safety of early discharge. It will also be convenient for use by pediatricians in their offices and by home health care agencies." Given the stock price drop since, maybe there is something we don't know that we don't know. We talked to a supposedly knowledgeable shortseller who, while claiming the stock was worth zero, had no hard news as to why. Therefore yesterday we called Dr. Holzman and asked if we are missing anything. Dr. Holzman replied that he still says the Chromatics device is as effective as blood and either that device or its equivalent (which does not exist anywhere yet, so far as Dr. Holzman knows) will be in virtually every hospital, every birthing facility and every pediatricians office. Dr. Holzman says he originally was skeptical about the Chromatic device but became convinced when he saw the test results. Last November Dr. Holzman became Director of Chromatic's Medical Advisory Board. Yes, he received the equivalent of 100,000 options at $7 and no cash. Would Dr. Holzman's options make him say it works when it doesn't? No. Our original March 16 buy recommendation estimated the global market size for infant blood tests for jaundice at 45,000,000 tests costing $1 billion. The obvious benefit to patients, and their parents, of the Chromatic device is not having to draw blood out of the heel of a day old babe. The obvious benefit to hospitals and/or lessors--there is no marginal use cost. One test device, assembled in quantity, will cost no more than several thousand dollars. The only negative in the stock we could find is the reluctance of Chromatic CEO Darby Macfarlane to make any preliminary announcements as to the status of any joint venture agreements with various medical device distributors. That kind of negative we can live with. Therefore, we recommend buying more CCSI